原发性胆汁性胆管炎综述
本文综述原发性胆汁性胆管炎的自身免疫性肝病特征,主要累及女性,以慢性破坏性小胆管肉芽肿性淋巴细胞性胆管炎及抗线粒体抗体为特点。治疗以体重剂量熊去氧胆酸为主,应答不足或不耐受者可加用FXR激动剂奥贝胆酸,超说明书可选贝特类。基线特征及胆红素、ALP用于风险分层和疗效评估,同时需关注瘙痒和疲劳等症状负担。
要点
- 原发性胆汁性胆管炎主要累及女性,以抗线粒体抗体为典型血清学标志。
- 一线治疗为体重剂量熊去氧胆酸,应答不足可加用奥贝胆酸。
- 基线年轻、男性、晚期疾病及胆红素、ALP用于风险分层和疗效评估。
核心结论
- 原发性胆汁性胆管炎是主要累及女性的自身免疫性肝病,治疗以改善胆汁淤积为主,并需关注症状负担。
研究设计与样本
- 本文为综述,未报告系统检索范围或样本量。
主要发现
- 疾病特征为慢性破坏性小胆管肉芽肿性淋巴细胞性胆管炎,伴抗线粒体抗体典型血清反应性。
- 患者进展为胆管减少、胆汁淤积和胆汁性纤维化的风险不一。
- 病因强调慢性免疫损伤与胆管上皮细胞反应的相互作用,并涉及遗传风险和环境触发因素。
关键数值与推荐
- licensed疾病修饰治疗为体重剂量口服熊去氧胆酸,聚焦改善胆汁淤积。
- 应答不足或不耐受者条件性许可加用FXR(NR1H4)激动剂奥贝胆酸。
- 超说明书治疗认可泛PPAR激动剂贝扎贝特作为替代,临床试验药物在研。
- 基线年轻、男性、晚期疾病及血清胆红素和ALP用于风险分层和评估治疗应答。
临床怎么用
- 以体重剂量熊去氧胆酸为一线治疗,评估应答后决定是否加用奥贝胆酸。
- 使用基线特征及胆红素、ALP进行风险分层和疗效监测。
- 平行评估和管理瘙痒、疲劳等症状负担。
局限性
- 本文为综述,未报告系统检索策略、纳入研究数量或证据质量评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis is an autoimmune liver disease that predominantly affects women. It is characterised by a chronic and destructive, small bile duct, granulomatous lymphocytic cholangitis, with typical seroreactivity for antimitochondrial antibodies. Patients have variable risks of progressive ductopenia, cholestasis, and biliary fibrosis. Considerations for the cause of this disease emphasise an interaction of chronic immune damage with biliary epithelial cell responses and encompass complex, poorly understood genetic risks and environmental triggers. Licensed disease-modifying treatment focuses on amelioration of cholestasis, with weight-dosed oral ursodeoxycholic acid. For patients who do not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed add-on therapy is with the FXR (NR1H4) agonist, obeticholic acid. Off-label therapy is recognised as an alternative, notably with the pan-PPAR agonist bezafibrate; clinical trial agents are also under development. Baseline characteristics, such as young age, male sex, and advanced disease, and serum markers of liver injury, particularly bilirubin and ALP, are used to stratify risk and assess treatment responsiveness. Parallel attention to the burden of patient symptoms is paramount, including pruritus and fatigue.
引用
- Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet. 2020. PMID: 33308474. doi:10.1016/S0140-6736(20)31607-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。